Mabel Mardones, M.D.

Dr. Mabel Mardones is a board-certified medical oncologist and hematologist with a specialty in breast cancer. She earned her degree from Loma Linda University in South California. She went on to complete internship and residency at University of Utah Clinics and Hospitals in Salt Lake City. After her residency, Dr Mardones completed her fellowship in Oncology and Hematology at Baylor University in Dallas, Texas. She currently serves as a partner of the Rocky Mountain Cancer Center, Denver Division. She was a previous partner with Texas Oncology also a US Oncology Practice.
She now serves as co chair for the breast cancer pathway taskforce for US Oncology and is a member of the US Oncology Breast Cancer Committee. She is also an executive committee member for breast cancer research SCRI/Sarah Cannon Cancer Research. She is also a member of the Precision Medicine Advisory Team for US Oncology Network. Dr Mardones is actively involved with clinical research. She has presented her work at San Antonio Breast Cancer Symposium and is principal and sub investigator for various USON/SCRI clinical trials.
She also participates in the ASCO Mentorship program and is invested in fostering career development particularly for minorities.
Financial relationships
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:PfizerTopic:Breast CancerDate added:07/16/2025Date updated:07/16/2025Relationship end date:01/09/2026
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:NovartisTopic:AdvisorDate added:07/16/2025Date updated:07/16/2025Relationship end date:08/15/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:StemlineTopic:AdvisorDate added:07/16/2025Date updated:07/16/2025Relationship end date:08/21/2026
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:illy LillyTopic:advisorDate added:07/16/2025Date updated:07/16/2025Relationship end date:01/07/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:AstrazenecaTopic:advisorDate added:07/16/2025Date updated:07/16/2025Relationship end date:12/25/2026
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:AgendiaTopic:advisorDate added:07/16/2025Date updated:07/16/2025Relationship end date:02/10/2026